 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...4344454647484950515253...266267» |
- Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001). (On Demand | Hall A; Poster Bd # 228a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1989;
P2
Recently, the combination of the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab received FDA-approval for the frontline treatment of non-resectable pleural mesothelioma...All pts with newly diagnosed peritoneal mesothelioma will be randomized 1:1 using a dynamic allocation Pocock-Simon procedure to receive carboplatin, pemetrexed and bevacizumab, with or without atezolizumab, every 21 days for four cycles...This trial was recently approved by the National Cancer Institute Central IRB and is activating at sites across the country. Clinical trial information: NCT05001880.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101). (On Demand | Hall A; Poster Bd # 227b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1988;
P2
Tumor and blood-based biomarkers will be included as exploratory biomarkers. Clinical trial information: NCT05647265.
- Imfinzi (durvalumab) / AstraZeneca
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R). (On Demand | Hall A; Poster Bd # 226a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1985;
P3
The recent CM 743 trial showed overall survival (OS) was longer in those assigned ipilimumab and nivolumab (ipi nivo) than standard chemotherapy, however the benefits were primarily in the subgroup with non-epithelioid histology... Treatment-na
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer. (On Demand | Hall A; Poster Bd # 224) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1983;
P2
We identified genomic features associated with treatment sensitivity/resistance. Clinical trial information: NCT03670056.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non (On Demand | Hall A; Poster Bd # 192) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1953;
However, if irAEs resulted in the discontinuation of therapy, these patients did have a shorter PFS and OS in the N alone arm. This difference was not observed in the IPI+N arm and those who experienced any irAEs in the IPI+N arm had an improved PFS.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Real-life efficacy of nivolumab plus ipilimumab combination in untreated, unresectable malignant pleural mesotheliomas: Result of French early access program (On Demand | Hall A; Poster Bd # 163) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1924;
P
This difference was not observed in the IPI+N arm and those who experienced any irAEs in the IPI+N arm had an improved PFS. While pt
- Keytruda (pembrolizumab) / Merck (MSD)
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial. (Live Stream | Hall B1) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1908;
P2/3
With a statistically significant improvement in mOS and acceptable tolerability. CP-pembro is an option for treatment na
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo. (Live Stream | Hall D1) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1356;
P2
Given the high survival rates, adjuvant ST is unlikely to give further benefit in these pts. In pts with pNR, addition of adjuvant ST with ongoing anti-PD1 or switch to BRAFi/MEKi appears to improve RFS and DMFS.
- Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort. (Available On Demand; Poster Bd # 469) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1274;
This retrospective analysis suggests that ICIs are effective and well tolerated in pts with MSI/dMMR advanced PDAC. Hence, our work supports the use of PD-1 inhibition in this group of pts with high unmet medical need.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable pancreatic adenocarcinoma. (Available On Demand; Poster Bd # 464) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1269;
P2
Further correlative analyses of the patient with a complete response and evaluation of in-field responses are ongoing. Clinical trial information: NCT04361162.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma. (Available On Demand; Poster Bd # 450) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1256;
P1/2
Study of tissue and gut microbiota highlights tumor and host-related changes. Immune infiltrate and gut microbiota composition lend themselves as predictors of anti-tumour efficacy of N+I combination.
- Molecular subtypes from comprehensive clustering from multi-omics dataset to predict the therapeutic efficacy of immunotherapeutic agent-based treatments in advanced hepatocellular carcinoma. (Available On Demand; Poster Bd # 433) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1239;
We identified clinically relevant molecular biomarkers from comprehensive clustering of a multi-omics dataset to predict the therapeutic efficacy and oncologic outcomes. Further prospective studies with clinical validation are warranted to confirm clinical implications.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade. (Available On Demand; Poster Bd # 412) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1219;
This study demonstrates that ipilimumab plus nivolumab has clinical activity in patients with advanced HCC who previously received anti-PD-(L)1 therapy with an acceptable safety profile, supporting this regimen as second line immune checkpoint inhibitor therapy in advanced HCC. Further studies are required to determine the optimal sequence of therapies in advanced HCC.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: The randomized phase 2 IKF-S628 Moonlight trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Available On Demand; Poster Bd # 371) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1179;
P2
a) Chemo plus dual checkpoint inhibition administered in parallel is associated with an increase in toxicity but not activity. b) Although associated with lower toxicity the use of sequential chemo followed by IO monotherapy is insufficient.
- Opdivo (nivolumab) / Ono Pharma, BMS
FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase 2 IKF-S628/AIO-STO-0417 (Moonlight) trial of the AIO. (Available On Demand; Poster Bd # 366) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1174;
P2
FLOT plus nivo may represent an option for select patients with aggressive, rapidly progressive disease. Clinical trial information: NCT03647969.
- Cyramza (ramucirumab) / Eli Lilly
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial. (Available On Demand; Poster Bd # 364) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1172;
P2
Sequential angiogenesis inhibition with anti-VEGFR-2 targeting therapy following immunochemotherapy might be a promising option to overcome resistance to immunotherapy, which warrants further investigations in a larger cohort. Clinical trial information: NCT03647969.
- Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial. (Available On Demand; Poster Bd # 348) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1157;
P2
Further analysis of baseline clinical and molecular data to better identify the subgroup of patients benefitting the most of trastuzumab/nivolumab/ipilimumab will be presented at the meeting. Clinical trial information: NCT03409848.
- Opdivo (nivolumab) / Ono Pharma, BMS
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. (Available On Demand; Poster Bd # 347) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1156;
P3
Clinical trial information: NCT02872116. >aper BICR.
- Yervoy (ipilimumab) / Ono Pharma, BMS
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio. (Available On Demand; Poster Bd # 380) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1133;
This study does not support further investigation of this regimen in this setting. Clinical trial information: ISRCTN84434175.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: Results of nivolumab plus ipilimumab treatment arm. (Available On Demand; Poster Bd # 414) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1090;
P1
To our knowledge, this is the first study in which checkpoint blockade therapy was administered for newly diagnosed glioblastoma prior to standard radiotherapy. Despite the short mPFS, mOS was suggestive of a potential long-term benefit from early CPI exposure, and three patients deferred chemoradiation greater than seven months.
- A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer. (Available On Demand; Poster Bd # 455a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1022;
P2
Adjuvant capecitabine or olaparib is recommended for all patients per local standard-of-care...Exploratory correlative studies will be performed on tumor and serum to characterize the immunologic impact of the intervention and to explore predictors of efficacy and toxicity. Clinical trial information: NCT03546686.
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Our Kent data of nivo ipi in front line #mesothelioma. In keeping with published literature. Reassuring #BTOG23 (Twitter) - Apr 26, 2023
- | Journal, Metastases: Immune combination possibilities in the first-line treatment of metastatic renal cell cancer (Pubmed Central) - Apr 26, 2023
Until 2018, the standard first-line therapy was the use of sunitinib or pazopanib...This year, the combination immunotherapy of ipilimumab and nivolumab was approved...The main objective of our summary is to present in chronological order the clinical trials of combination therapies already approved in Europe, as well as the most recent phase III clinical trials. It is also intended to provide a brief practical guide on how to decide on first-line therapy based on the results of these trials.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date, Tumor mutational burden, IO biomarker: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (clinicaltrials.gov) - Apr 26, 2023
P1/2, N=140, Completed, Sponsor: National Cancer Institute (NCI)
It is also intended to provide a brief practical guide on how to decide on first-line therapy based on the results of these trials. Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Mar 2023
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Clinical Trial,Phase III, Journal, Adverse events: Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). (Pubmed Central) - Apr 25, 2023
P3
Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Mar 2023 The graphical approaches we proposed enable a more comprehensive and intuitive evaluation of toxicity types by treatment groups, which is not apparent in tabular and descriptive reporting methods.
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
After 4 years (ph2 DART trial of Nivo/Ipi), another study with important implications in the management of the rare and lethal #neuroendocrine #cervicalcancer! Thank you Prof @Frumovitz and NeCTuR team for accelerating #rarecancer treatment! @MichalisLiontos @ENYGO_official (Twitter) - Apr 25, 2023
- | Tagrisso (osimertinib) / AstraZeneca, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy: Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (clinicaltrials.gov) - Apr 25, 2023
P1, N=26, Recruiting, Sponsor: University of Utah
The graphical approaches we proposed enable a more comprehensive and intuitive evaluation of toxicity types by treatment groups, which is not apparent in tabular and descriptive reporting methods. Trial primary completion date: Apr 2023 --> Apr 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Trial completion date: Lung-Map Sub-Study: Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (clinicaltrials.gov) - Apr 25, 2023
P3, N=275, Active, not recruiting, Sponsor: SWOG Cancer Research Network
Trial primary completion date: Apr 2023 --> Apr 2024 Trial completion date: Apr 2023 --> Apr 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (clinicaltrials.gov) - Apr 25, 2023
P2, N=46, Active, not recruiting, Sponsor: Brown University
Trial completion date: Apr 2023 --> Apr 2024 Recruiting --> Active, not recruiting
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal (Auditorium A, Level 0) - Apr 24, 2023 - Abstract #ESMOGI2023ESMO_GI_170;
P2
The addition of I to N trended in favor for PFS and OS but was not statistically significant in refractory, unresectable or metastatic SCCA pts, resulting in increased toxicity. Ongoing correlative studies for NCI9673 to characterize responses to single vs. combined immunotherapy in this population seek to provide rationale for the design of future studies.
- |||| Welireg (belzutifan) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Next-generation sequencing: For a pt progressing on Ipi Nivo -> NGS with VHL somatic mutation( germline negative) Next best option - Cabo vs Cabo + Belzutifan vs Belzutifan vs other Prob should have asked as a poll question .. @tompowles1 @DrChoueiri (Twitter) - Apr 24, 2023
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
B cell IGHE expression is higher in melanoma patients who develop immune-related arthritis post combination checkpoint immunotherapy (Level 3 - Room 331) - Apr 24, 2023 - Abstract #WCD2023WCD_2067;
INTRODUCTION: Immune-related adverse events (irAE) commonly occur following combination immunotherapy with ipilimumab and nivolumab (cICB) and presents a major challenge to clinicians. B cell IGHE expression is higher in patients who develop arthritis-irAEs, suggesting a potential role in disease pathogenesis
- | Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Journal, Tumor microenvironment: A novel inflammation-related signature for predicting prognosis and characterizing the tumor microenvironment in colorectal cancer. (Pubmed Central) - Apr 24, 2023
The IRG risk score predicted the clinical benefit of ipilimumab...These IRGs in the risk model regulated stromal and immune components in the tumor microenvironment and could serve as potential therapeutic targets in CRC. TIMP1 promoted macrophage migration and meditated macrophage M2 polarization by activating ERK1/2/CLAM1 and CCL2.
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial termination, IO biomarker: Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) (clinicaltrials.gov) - Apr 24, 2023
P1/2, N=15, Terminated, Sponsor: Weill Medical College of Cornell University
TIMP1 promoted macrophage migration and meditated macrophage M2 polarization by activating ERK1/2/CLAM1 and CCL2. Completed --> Terminated; Slow accrual
- | Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma (clinicaltrials.gov) - Apr 24, 2023
P2, N=52, Recruiting, Sponsor: Abramson Cancer Center at Penn Medicine
Completed --> Terminated; Slow accrual Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Jun 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: NCI-2018-03329: Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer (clinicaltrials.gov) - Apr 21, 2023
P1, N=7, Active, not recruiting, Sponsor: Claire Verschraegen
Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Jun 2024 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Combination therapy, Metastases: Mike Atkins discusses immune combination therapy #ICKS23 He sets out a compelling argument for ipi/nivo for advanced disease, but doesn’t address the -ve adjuvant trial. @AlbigesL set out the strong RR PFS data for VEGF/PD-1, but there is uncertainty around long-term durability. (Twitter) - Apr 20, 2023
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Monotherapy, Metastases: CheckMate714randomised clinical trial to evaluate nivolumab+ipilimumab vs nivolumab monotherapy as 1st-line tt for recurrent or metastatic sq cell ca of head&neck,in pts with platinum-refractorySCCHN, did not meet its primary endpoint of objective response rate in platinum-refrac (Twitter) - Apr 20, 2023
- A case report of a FGFR activation and genetic variability in metastatic sinonasal mucosal melanoma () - Apr 19, 2023 - Abstract #EADO2023EADO_443;
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 A switch to second-line Lenvatinib and Pembrolizumab followed due to progressive disease...According to these results, we have received approval to start Erdafitinib (Balversa
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
The Value of Adjuvant Radiotherapy in the Treatment of Melanoma: a retrospective multi-center analysis () - Apr 19, 2023 - Abstract #EADO2023EADO_433;
In most cases, radiotherapy is utilized as an upfront strategy adjunct to subsequent systemic treatment. Considering the marked effect of systemic adjuvant therapies on recurrence-free survival and no trend towards improved landmark RFS rates in the present data compared to the literature, it remains unclear whether combining RT and systemic therapy can improve RFS outcomes through enhanced local disease control and potential abscopal effects.
- || Yervoy (ipilimumab) / Ono Pharma, BMS
A good reminder that everything we think we know about immunology is proven wrong within 5 years… fascinating point with relevance to ipilimumab! (Twitter) - Apr 19, 2023
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Checkpoint inhibition: Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases (clinicaltrials.gov) - Apr 19, 2023
P1, N=10, Recruiting, Sponsor: Emory University
Considering the marked effect of systemic adjuvant therapies on recurrence-free survival and no trend towards improved landmark RFS rates in the present data compared to the literature, it remains unclear whether combining RT and systemic therapy can improve RFS outcomes through enhanced local disease control and potential abscopal effects. Trial completion date: Mar 2023 --> Mar 2025 | Trial primary completion date: Mar 2023 --> Mar 2024
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Metastases: First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened? (Pubmed Central) - Apr 19, 2023
Trial completion date: Mar 2023 --> Mar 2025 | Trial primary completion date: Mar 2023 --> Mar 2024 No abstract available
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Metastases: Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. (Pubmed Central) - Apr 19, 2023
P3
Nivolumab plus ipilimumab showed a favorable safety profile compared with EXTREME. There continues to be a need for new therapies in patients with R/M SCCHN.
- ||| Trial termination, Checkpoint inhibition: NLG-0304: Immunotherapy Study for Patients With Stage IV Melanoma (clinicaltrials.gov) - Apr 18, 2023
P2b, N=47, Terminated, Sponsor: NewLink Genetics Corporation
There continues to be a need for new therapies in patients with R/M SCCHN. Active, not recruiting --> Terminated; Withdrawal of IND
- | Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron
Trial completion date: CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease (clinicaltrials.gov) - Apr 18, 2023
P2, N=34, Active, not recruiting, Sponsor: Diwakar Davar
Active, not recruiting --> Terminated; Withdrawal of IND Trial completion date: Mar 2023 --> Dec 2023
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, IO biomarker: CheckMate 238: Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (clinicaltrials.gov) - Apr 18, 2023
P3, N=906, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Mar 2023 --> Dec 2023 Trial completion date: Jan 2026 --> Oct 2024
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Apr 18, 2023
P1/2, N=1163, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jan 2026 --> Oct 2024 Trial completion date: Apr 2023 --> Dec 2023
- || Opdivo (nivolumab) / BMS
Trial completion date, Monotherapy, IO biomarker: CheckMate 039: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov) - Apr 18, 2023
P1/2, N=316, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Apr 2023 --> Dec 2023 Trial completion date: Nov 2022 --> Dec 2023
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial withdrawal: CERAD-IMMUNE: Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients (clinicaltrials.gov) - Apr 18, 2023
P2, N=0, Withdrawn, Sponsor: Universit
Trial completion date: Nov 2022 --> Dec 2023 N=55 --> 0 | Not yet recruiting --> Withdrawn